Key result
RotaTeq vaccination led to asymptomatic viral shedding in 17% of vaccinated children under 2 years of age, with detection lasting up to 8 months and primarily involving genotype G1.
Why the study?
Does rotavirus vaccination lead to long-term viral shedding in nonimmunocompromised children?
Does rotavirus vaccination lead to long-term viral shedding in nonimmunocompromised children?
Asymptomatic long-time shedding of RotaTeq vaccine viruses is not uncommon in nonimmunocompromised children and is frequently associated with genotype G1.
Answers are grounded in this paper and cite their sources.
Prolonged asymptomatic shedding after RotaTeq may warrant household precautions in vulnerable contacts; leaves open prospective studies on transmission risk.
We conducted a survey on the presence of RotaTeq vaccine viruses in infants hospitalized with respiratory infection, and detected shedding in 17% of children (<2 years of age) who had ever received the vaccine. The latest detection was at the age of 8 months. We conclude that asymptomatic long-time shedding of RotaTeq viruses is not uncommon, and is particularly associated with genotype G1.
No takes yet. Share an insight, caveat, or question.
Markkula et al. (2014) studied this question. RotaTeq vaccination led to asymptomatic viral shedding in 17% of vaccinated children under 2 years of age, with detection lasting up to 8 months and primarily involving genotype G1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: